K

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Director – Drug Substance Commercial Manufacturing

Bioprocess & BiomanufacturingConfirmed live in the last 24 hours
Full-timeRemote

About the Job

Requirements

  • At least 10 years of relevant experience in drug substance technical operations, including at least 5 years of leadership accountable for technology transfer and process validation at external manufacturers through commercial supply.
  • Hands-on experience in MSAT or technical operations for commercial-stage drug substance manufacturing at CDMOs, including continued process verification, troubleshooting, and lifecycle change management.
  • Experience overseeing commercial drug substance manufacturing campaigns at external partners, including batch record review, deviation response, and recovery of at-risk supply.
  • Deep expertise in synthetic peptide drug substance manufacturing, including synthesis, purification, impurity control, scale-up, and process troubleshooting.
  • Demonstrated experience in technology transfer, process characterization, control strategy implementation, and process performance qualification.
  • Experience driving operational excellence and continuous improvement in yield, cycle time, cost, and robustness at CDMOs or external manufacturing sites.
  • Strong understanding of CDMO operating models, capabilities, capacity constraints, and commercial drivers, with experience establishing governance and managing external partner performance.
  • Experience contributing to drug substance CMC documentation for marketing applications and supporting regulatory review for inspection readiness.
  • Strong understanding of current Good Manufacturing Practice, pharmaceutical quality systems, analytical and stability requirements, comparability, and global drug substance regulatory expectations.
  • Proven ability to build and develop technical teams and deliver multiple workstreams with clear priorities, budgets, and accountability.
  • Strong scientific judgment and business acumen, including evaluating technical evidence, communicating tradeoffs, and influencing cross-functional decisions.
  • Ability to travel domestically and internationally to CDMOs and company sites.
  • A bachelor's degree in chemistry, chemical engineering, pharmaceutical sciences, biotechnology, or a related field is required.

Responsibilities

  • Lead drug substance transfer to assigned CDMOs, including process knowledge packages, equipment and facility fit assessments, scale-up, engineering batches, and transfer acceptance criteria; translate network drug substance strategy into an execution plan with milestones, resources, and risks through process performance qualification, registration, and launch.
  • Lead drug substance technology transfer, process validation, commercialization, and lifecycle management across CDMO partners, ensuring successful scale-up, process performance qualification execution, regulatory approval, launch readiness, and continuous supply.
  • Serve as the technical owner of commercial peptide drug substance processes, overseeing manufacturing operations, process performance, yield, quality, robustness, control strategies, and continuous improvement initiatives.
  • Drive process monitoring, comparability assessments, investigations, change control, corrective and preventive actions, and continued process verification in partnership with Quality, Analytical, CMC Development, Regulatory, and Supply Chain functions.
  • Provide technical leadership for CDMO development and manufacturing activities, including process transfers, method implementation, campaign readiness, deviation management, risk mitigation, capacity planning, and operational governance.
  • Author and support drug substance CMC documentation, regulatory submissions, inspection readiness activities, and health authority interactions, ensuring manufacturing execution aligns with regulatory commitments.
  • Evaluate and support CDMO selection, audits, technical agreements, process changes, capacity strategies, business continuity planning, and external spend management.
  • Build, lead, and develop MSAT, manufacturing oversight, and technology transfer teams while fostering cross-functional and external partnerships to achieve business, quality, and supply objectives.
  • Provide sponsor oversight of CDMO process development when assigned CDMOs are developing new processes for the company.
  • Ensure agreed processes and methods are implemented at CDMOs exactly as approved, without unapproved changes.
  • Coordinate with peer drug substance leaders to maintain consistent process knowledge, controls, and analytical performance across the network.

Desired Qualifications

  • Commercial launch experience is strongly preferred.
  • Experience with peptide therapeutics at commercial scale.
  • Experience managing a multi-CDMO network with distinct quality systems and timelines.
  • Experience with a first product launch, global drug substance networks, supply continuity planning, and post-approval process improvements.
  • Experience with minimum annual volume and take-or-pay commitments, including assessing financial exposure and aligning operations to contractual thresholds.
  • Hands-on plant or CDMO experience combined with sponsor-side oversight, including person-in-plant support during commercial campaigns.
  • Experience providing sponsor oversight of CDMO process development alongside commercial supply.
  • Experience with solid-phase, solution-phase, or hybrid peptide synthesis, preparative chromatography, commercial isolation, and drying.
  • Experience with design of experiments, statistical process evaluation, and continued process verification.
  • Lean, Six Sigma, or equivalent continuous improvement training or certification.
  • An advanced degree (M.S., Ph.D., or equivalent).

About the Company

Kailera Therapeutics

Clinical-stage obesity and metabolic drugs developer

Kailera Therapeutics focuses on obesity and related metabolic conditions by acquiring and developing clinical-stage drug candidates and moving them toward commercialization. Its lead asset, KAI-9531, is an injectable dual agonist of GLP-1 and GIP receptors for obesity and type 2 diabetes, and the pipeline includes an oral GLP-1 agonist (KAI-7535), an oral tablet form of KAI-9531, and an injectable tri-agonist targeting GLP-1, GIP, and glucagon receptors (KAI-4729). The company differentiates itself by sourcing assets outside of early research, pursuing a mix of injectable and oral therapies, and leveraging a high-profile leadership team and substantial funding to progress a broad portfolio under external licenses. Kailera’s goal is to advance multiple metabolic disease therapies from clinical development toward commercialization to improve outcomes for patients with obesity and related conditions.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2024

Recently Posted Jobs

Explore more opportunities at Kailera Therapeutics

See more jobs